Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Snapshot

The global gastrointestinal stromal tumor (GIST) therapeutics market is expected to garner a market value of US$ 890 Million in 2023 and is expected to accumulate a market value of US$ 1593 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. Growth of the gastrointestinal stromal tumor (GIST) therapeutics market can be attributed to growing prevalence of GIST in the aging population across the globe. The market for gastrointestinal stromal tumor (GIST) therapeutics registered a CAGR of 3.5% in the historical period 2018 to 2022

Gastrointestinal Stromal Tumor (GIST) Therapeutics refers to the medical treatments used to manage GIST, a type of cancer that occurs in the cells of the gastrointestinal tract. The goal of GIST therapeutics is to control or eliminate the cancer cells and reduce symptoms. The treatment options for GIST include surgery, targeted therapy with tyrosine kinase inhibitors (TKIs), radiation therapy, and chemotherapy. The choice of therapy depends on the size, location, and stage of the tumor, as well as the patient's overall health. The goal is to provide the most effective treatment while minimizing side effects.

Report Attribute Details
Expected Market Value (2023) US$ 890 Million
Anticipated Forecast Value (2033) US$ 1593 Million
Projected Growth Rate (2023 to 2033) 6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Gastrointestinal stromal tumor (GIST) therapeutics reflected a value of 3.5% during the historical period, 2018 to 2022.

The Gastrointestinal Stromal Tumor (GIST) Therapeutics Market was growing during the period from 2018 to 2022. The growth was primarily driven by the increasing incidence of gastrointestinal stromal tumors and the approval of new drugs for the treatment of GIST. In addition, the rising awareness about GIST and the availability of advanced therapies are also contributing to the growth of the market. However, the high cost of treatment and the limited number of approved drugs may hinder the growth of the market.

Thus, the market for Gastrointestinal stromal tumor (GIST) therapeutics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Gastrointestinal Stromal Tumor (GIST) Therapeutics Market?

Demand for effective therapies driving growth for GIST therapeutics market

The incidence of GIST is increasing worldwide, which is driving the demand for effective treatment options. As GIST is a difficult cancer to treat, there remains a significant unmet medical need for new and effective therapies. Moreover, development of new technologies, such as tyrosine kinase inhibitors (TKIs), has led to improved treatment outcomes for patients with GIST.

Furthermore, increasing awareness about GIST and its treatment options, among healthcare providers and patients, is driving demand for GIST therapeutics. In addition, governments around the world are providing support for cancer research and drug development, which is helping to drive growth in the GIST therapeutics market.

Availability of various treatments creating lucrative opportunities for GIST therapeutics market

As GIST cannot be completely treated with surgery, the dependency on various therapeutics has increased. Moreover, healthcare professionals are suggesting different therapeutics methods that would cater to the condition of the patients.

Surgery: Surgical removal of the tumor is the primary treatment option for localized GISTs.

Imatinib: This is a tyrosine kinase inhibitor (TKI) that targets the KIT and PDGFRA genes that are often mutated in GISTs. Imatinib is the first-line therapy for advanced GISTs.

Sunitinib: This is another TKI that is used as a second-line treatment for patients who have developed resistance to imatinib.

Regorafenib: This is another TKI that is used as a third-line treatment for patients who have become resistant to both imatinib and sunitinib.

Radiation therapy: Radiation therapy may be used in conjunction with surgery or as palliative treatment for GISTs that cannot be surgically removed.

Chemotherapy: Chemotherapy is generally not effective in treating GISTs, but it may be used in combination with other therapies.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Gastrointestinal Stromal Tumor (GIST) Therapeutics Market?

Lengthy approval process and drug resistance restricting market growth

The cost of GIST treatments, especially targeted therapies and other innovative drugs is high. This, in turn, limits access to these treatments for some patients. GIST is a relatively rare type of cancer, which means that the market for GIST therapeutics is smaller compared to other cancer indications.

As patents for GIST treatments expire, generic versions of these drugs may become available, which can decrease the market share and profitability of brand-name treatments. Some patients with GIST may develop resistance to TKIs, which can limit the effectiveness of these treatments over time.

The approval process for new drugs can be lengthy and expensive, and there is always the risk that a new treatment may not be approved by regulatory agencies. Some GIST treatments can cause adverse effects, such as nausea, vomiting, fatigue, and low blood counts, which can impact patient quality of life and limit the use of these treatments. All these factors are hampering the growth of the GIST market.

Region-Wise Insights

Increasing Healthcare Expenditure in North America Gastrointestinal Stromal Tumor (GIST) Therapeutics Market?

Introduction of new and innovative therapies creating lucrative opportunities for GIST therapeutics

The North American market for Gastrointestinal Stromal Tumor (GIST) therapeutics is one of the largest and most mature markets globally, driven by factors such as a large and aging patient population, high levels of healthcare spending, and a strong presence of pharmaceutical companies. The United States is the largest market for GIST therapeutics in North America, accounting for the majority of sales in the region.

In recent years, the North American market for GIST therapeutics has seen steady growth due to the increasing incidence of GIST, the introduction of new and innovative therapies, and growing demand for effective treatments. The availability of targeted therapies, such as tyrosine kinase inhibitors (TKIs), has been a major driver of growth in the market, as these drugs have proven to be highly effective in treating GIST. Thus, North America is expected to possess 39% market share for GIST therapeutics market in 2023.

Availability of Targeted Therapies Bolstering Growth of Gastrointestinal Stromal Tumor (GIST) Therapeutics Market in Asia Pacific?

Growing prevalence of GIST in aging population propelling market growth

The Asia Pacific market for gastrointestinal stromal tumor (GIST) therapeutics is a rapidly growing market, driven by factors such as increasing incidence of GIST, rising levels of healthcare spending, and a growing middle-class population. The market is expected to continue to grow in the coming years, driven by factors such as the increasing availability of targeted therapies, such as tyrosine kinase inhibitors (TKIs), and the growing awareness of GIST among healthcare providers and patients.

Despite these challenges, the Asia Pacific market for GIST therapeutics is expected to continue to grow in the coming years, driven by increasing demand for effective treatments, advances in research and development, and improving economic conditions in the region. The market is also likely to benefit from the growing aging population and the increasing incidence of GIST, which are expected to drive demand for GIST treatments in the future. Thus, Asia Pacific is expected to hold 31% market share for GIST therapeutics market in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

Comprehensive Care for GIST Patients in Hospitals Making them a Go-To Option for GIST Therapeutics Market?

Presence of innovative drugs and technology making hospitals a viable option for treatment of GIST therapeutics

Hospitals have a high level of expertise in treating complex and rare diseases such as GIST, and often have a dedicated team of specialists who are experienced in diagnosing and treating the condition. In addition, hospitals provide comprehensive care for GIST patients, including surgery, chemotherapy, radiation therapy, and targeted therapies such as tyrosine kinase inhibitors (TKIs). Access to the latest technologies and treatments, including innovative drugs and cutting-edge diagnostic and therapeutic tools, which can improve patient outcomes are making hospitals a go-to option for patients suffering frm GIST.

Moreover, strict quality and safety standards ensure that patients receive high-quality care and are protected from medical errors. In addition, hospitals offer the convenience of having all necessary diagnostic and therapeutic services in one location, reducing the need for multiple trips to different healthcare providers. Thus, hospitals are expected to procure 45% market share for GIST therapeutics market in 2023.

Market Competition

Key players in the gastrointestinal stromal tumor (GIST) therapeutics market are Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc, Cogent Biosciences, Inc, Plexxikon Inc, Theseus Pharmaceuticals, Exelixis, Inc, Ipse, Bristol-Myers Squibb and Takeda

  • In June 2022, Taiho Pharmaceutical Co., Ltd. announced that it has obtained manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for the oral heat shock protein (HSP) 90 inhibitor Jeselhy® Tablets 40 mg for the indication of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.
  • Cogent Biosciences, Inc, another key player in the gastrointestinal stromal tumor (GIST) therapeutics market is focusing on integrating technology to understand the nature of the ailment and innovate medication for the same.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 890 Million
Market Value in 2033 US$ 1593 Million
Growth Rate CAGR of 6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Drug Type
  • Therapy
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Argentina
  • Germany
  • United kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa
Key Companies Profiled
  • Arog Pharmaceuticals
  • Taiho Pharmaceutical
  • Turning Point Therapeutics, Inc.
  • Cogent Biosciences, Inc.
  • Plexxikon Inc.
  • Theseus Pharmaceuticals
  • Exelixis, Inc.
  • Ipsen
  • Bristol-Myers Squibb
  • Takeda
Customization Available Upon Request

Key Segments Profiled in the Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry Survey

Drug Type:

  • Imatinib
  • Ripretinib
  • Crenolanib
  • Regorafenib
  • Avapritinib
  • Sunitinib
  • Entrectinib
  • Larotrectinib

Therapy:

  • Targeted therapy
  • Chemotherapy
  • Radiation therapy

End User:

  • Hospitals
  • Clinics
  • Specialized Cancer Treatment Centres

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

Which Application Holds Lucrative Opportunities?

The hospital segment holds high revenue potential.

Which Countries Dominate the Global Market?

The United States and China are estimated to dominate the global market.

What is the Growth Forecast for the Gastrointestinal Stromal Tumor Therapeutics Market?

The market is forecast to register a CAGR of 6% through 2033.

How is the Historical Performance of the Market?

During 2018 to 2022, the market registered a CAGR of 3.5%.

Which is the Top Trend in the Gastrointestinal Stromal Tumor Therapeutics Market?

The adoption of chemotherapy treatment disrupts the current market trends.

Table of Content

1. Executive Summary | Gastrointestinal Stromal Tumor (GIST) Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Imatinib

        5.3.2. Ripretinib

        5.3.3. Crenolanib

        5.3.4. Regorafenib

        5.3.5. Avapritinib

        5.3.6. Sunitinib

        5.3.7. Entrectinib

        5.3.8. Larotrectinib

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033

        6.3.1. Targeted therapy

        6.3.2. Chemotherapy

        6.3.3. Radiation therapy

    6.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By End-user , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user , 2023 to 2033

        7.3.1. Hospitals

        7.3.2. Clinics

        7.3.3. Specialized Cancer Treatment Centres

    7.4. Y-o-Y Growth Trend Analysis By End-user , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By End-user , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Drug Type

        9.2.3. By Therapy

        9.2.4. By End-user

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Type

        9.3.3. By Therapy

        9.3.4. By End-user

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Drug Type

        10.2.3. By Therapy

        10.2.4. By End-user

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Type

        10.3.3. By Therapy

        10.3.4. By End-user

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Drug Type

        11.2.3. By Therapy

        11.2.4. By End-user

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Type

        11.3.3. By Therapy

        11.3.4. By End-user

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Drug Type

        12.2.3. By Therapy

        12.2.4. By End-user

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Therapy

        12.3.4. By End-user

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Drug Type

        13.2.3. By Therapy

        13.2.4. By End-user

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Therapy

        13.3.4. By End-user

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Drug Type

        14.2.3. By Therapy

        14.2.4. By End-user

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Therapy

        14.3.4. By End-user

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Drug Type

        15.2.3. By Therapy

        15.2.4. By End-user

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Therapy

        15.3.4. By End-user

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Drug Type

            16.1.2.2. By Therapy

            16.1.2.3. By End-user

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Drug Type

            16.2.2.2. By Therapy

            16.2.2.3. By End-user

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Drug Type

            16.3.2.2. By Therapy

            16.3.2.3. By End-user

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Drug Type

            16.4.2.2. By Therapy

            16.4.2.3. By End-user

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Drug Type

            16.5.2.2. By Therapy

            16.5.2.3. By End-user

    16.6. United kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Drug Type

            16.6.2.2. By Therapy

            16.6.2.3. By End-user

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Drug Type

            16.7.2.2. By Therapy

            16.7.2.3. By End-user

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Drug Type

            16.8.2.2. By Therapy

            16.8.2.3. By End-user

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Drug Type

            16.9.2.2. By Therapy

            16.9.2.3. By End-user

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Drug Type

            16.10.2.2. By Therapy

            16.10.2.3. By End-user

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Drug Type

            16.11.2.2. By Therapy

            16.11.2.3. By End-user

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Drug Type

            16.12.2.2. By Therapy

            16.12.2.3. By End-user

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Drug Type

            16.13.2.2. By Therapy

            16.13.2.3. By End-user

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Drug Type

            16.14.2.2. By Therapy

            16.14.2.3. By End-user

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Drug Type

            16.15.2.2. By Therapy

            16.15.2.3. By End-user

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Drug Type

            16.16.2.2. By Therapy

            16.16.2.3. By End-user

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Drug Type

            16.17.2.2. By Therapy

            16.17.2.3. By End-user

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Drug Type

            16.18.2.2. By Therapy

            16.18.2.3. By End-user

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Drug Type

            16.19.2.2. By Therapy

            16.19.2.3. By End-user

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Drug Type

            16.20.2.2. By Therapy

            16.20.2.3. By End-user

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Drug Type

            16.21.2.2. By Therapy

            16.21.2.3. By End-user

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Drug Type

        17.3.3. By Therapy

        17.3.4. By End-user

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Arog Pharmaceuticals

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Taiho Pharmaceutical

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Turning Point Therapeutics, Inc.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Cogent Biosciences, Inc.

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Plexxikon Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Theseus Pharmaceuticals

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Exelixis, Inc.

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Ipsen

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Bristol-Myers Squibb

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Takeda

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Rare Gastrointestinal Diseases Treatment Market

Published : August 2023

Healthcare

Gastrointestinal Stent Market

Published : February 2023

Explore Healthcare Insights

View Reports

Gastrointestinal Stromal Tumor (GIST) Therapeutics Market